This document is a publication of a European patent application (EP4630419A1) for novel substituted pyrazine-carboxamide-imidazopyridine derivatives. The application was published by the European Patent Office (EPO) on March 18, 2026, with Boehringer Ingelheim International GmbH as the applicant. The patent claims relate to compounds with potential therapeutic uses, including treatments for neurological conditions and cancer.

This publication represents the grant of a patent, not a regulatory rule or enforcement action. It does not impose new compliance obligations on pharmaceutical companies or drug manufacturers. However, it signifies intellectual property protection for the named derivatives, which may impact future research and development in related therapeutic areas. Companies operating in the pharmaceutical sector should be aware of this patent's existence as it pertains to their intellectual property landscape.